Epimune GmbH and Tanner Pharma Group enter into Distribution Partnership for Latin America
Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited ("TannerLAC"), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the Latin American region. TannerLAC provides pharmaceutical, biotech, and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets.
Under the license agreement, TannerLAC will be responsible for product registrations, sales, and marketing activities in the Latin American region. First approvals are expected within the second half of 2021.
Carolina Cortez, EVP of TannerLAC, commented, “We are thrilled to partner with Epimune to be able to bring this revolutionary technology to Latin America to help immunodeficient patients have access to the i.Mune TBNK in-vitro diagnostic test that will facilitate early screening and monitoring which will help physicians make the best decisions when treating them.”
“We are very pleased to work with TannerLAC as a highly committed partner in making our i.Mune TBNK product widely available in Latin America,” said Uwe Staub, PhD, CEO of Epimune GmbH. “This partnership provides quick and professional access to the Latin American market which we consider very important for our product. We are looking forward to working closely with the TannerLAC team over the coming months. Together we will offer solutions to this market over the years ahead.”